TRV GP IV, LLC
CIK
1688325
Location
Boston, MA
Portfolio Value
Small
$266,903,734
Diversification
Highly concentrated
Filing Date
Global Rank
#3,626
/ 8,592
▲ 197
Top Industry
Biotechnology
100.0%
3Y Alpha vs SPY
-0.3%
Period ended 3 months ago
Filed May 7, 2026 · 43d
25 quarters · since Mar 2020
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+75.7%
SPY
+76.8%
Annualised alpha
-0.3%
Max drawdown
−89.9%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
2 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
50.0%
−22.6 pts
Top 5
100.0%
0.0 pts
Top 10
100.0%
0.0 pts
HHI
5,000
Highly concentrated−1,026
Portfolio Trend
25 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $266,903,734 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedNo qualifying positions this quarter.
Trimmed
Positions the filer reduced
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | −1,500,000 | 6,374,574 | $133,356,088 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarterNo qualifying positions this quarter.
Sold Out
Positions the filer fully exitedNo qualifying positions this quarter.
2 positions ·
$266,903,734 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Held | 4,473,958 | $133,547,646 | 50.04% | |
| TNGX |
Tango Therapeutics, Inc.
Healthcare
|
Reduced | 6,374,574 | $133,356,088 | 49.96% |